General discussion, page-7346

First 7346 Last

Mujtabazafar

138 Posts.

104

25/08/21

14:37

Post #: 55562577

Originally posted by thevinnys: ↑
Hey @Mujtabazafar

I think your question is best answered by aligning your Market Cap projections with some positive news that may come from some of the trials.
For instance some positive news from our IHL-42X Trials are due by end of Q4. (dec say)

That positive news should propel the SP to $1.00 in of itself Mkt Cap circa $1BLN (if we are not already at that level by then)
There is no other medicated therapy for sleep apnoea, this will be huge news and could actually take us a lot higher seeing that will have a bunch of more knowledgeable investors whom would appreciate the value investment here.

Then for the remainder of your Market Cap projections go to the next Trial and guestimate the "Probability of Success" which is the true driver of valuation. Let us know what you come up with we will all be very interested to know your thoughts.

Good luck @Mujtabazafar
Expand
Hi TV,
Thanks for the reply. Based on the info you provided, below is my back of the envelope estimation.
Dsiclosure: I dont have a bio/med background so I might have grossly over/under estimated the potential of upcoming milestones. Please feel free to correct me and adjust the projections.

Timeline
Expected Events
Share Price Projection
1
Dec 2021
1.IHL 42X – Complete Phase 2 Trials – Submit FDA Pre-IND
2.IHL – 216A - Complete Phase 2 Trials – Submit FDA Pre-IND
3.IHL 675A – Complete Phase 1 Trials (IBD, ILD, RA)
4.PSI – GAD (Commence Phase 2A trials)
75 – 99 Cents
2
March 2022
1.IHL 675A - Submit FDA Pre-IND
$0.8 to $1.2
3
September 2022
1.IND submission for IHL 42X
2.IND submission for IHL 216A
3.Submission of FDA Pre-IND for Phase 2 trials of IHL 675 A )(IBD, ILD)
4.IND Submission for PSI – General Anxiety Disorder
$1 - $1.5
4
June 2023
1.IND submission for IHL 675 (RA)
$1.2 - $1.75

	Timeline	Expected Events	Share Price Projection
1	Dec 2021	1.IHL 42X – Complete Phase 2 Trials – Submit FDA Pre-IND 2.IHL – 216A - Complete Phase 2 Trials – Submit FDA Pre-IND 3.IHL 675A – Complete Phase 1 Trials (IBD, ILD, RA) 4.PSI – GAD (Commence Phase 2A trials)	75 – 99 Cents
2	March 2022	1.IHL 675A - Submit FDA Pre-IND	$0.8 to $1.2
3	September 2022	1.IND submission for IHL 42X 2.IND submission for IHL 216A 3.Submission of FDA Pre-IND for Phase 2 trials of IHL 675 A )(IBD, ILD) 4.IND Submission for PSI – General Anxiety Disorder	$1 - $1.5
4	June 2023	1.IND submission for IHL 675 (RA)	$1.2 - $1.75

IHL Price at posting: 40.0¢ Sentiment: Buy Disclosure: Held

11 Upvote

1 Great analysis

Top Stories

LU7

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Failure to report prompts ASX to impose multiple company suspensions

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

DRE

Dreadnought (ASX:DRE) reports gold hit above 27 grams per tonne